content top

Retinal Inflammation and DME: Novel Approach

Media not available due to technical recording problems. EVRS is very sorry for the inconvenience.   Objectives: To evaluate the efficacy of topical nepafenac in patients with impaired blood-retinal barrier (BRB) in the macular area. Methods: In a prospective pilot study 15 eyes were included; in the first visit and controls complete eye examination was performed (mean follow-up: 79 days). Visual acuity (VA), central thickness (CT) and...

Read More

Focal RPE Angiographic Leaks Visualized by En-face OCT: “A New Diagnostic Technique”

Advantages: In central serous chorioretinopathy (CSC), we evaluated the optical coherence tomography (OCT) images of the retinal pigment epithelium (RPE) obtained by scanning in an “en-face” direction (parallel to the retinal surface), and compared them, firstly, with the morphological findings in the unaffected eyes and secondly, with the leakage points on fluorescein angiography (FA). Methods: In prospective study 42 eyes of 21...

Read More

Treatment of Diffuse Diabetic Macular Edema: Bevacizumab versus Multifocal Photocoagulation

http://www.evrs.eu/medias/2009/congress/Diabetes.flv Authors: Vladimir Poposki, Daniel  Vilaplana, Daniela Poposka, Isaac Alarcón, O.  Marínez-Giralt, M. Castilla , Barcelona, Spain Advantages: To evaluate the efficacy of Bevacizumab regarding photocoagulation in the treatment of diffuse diabetic macular edema (EMDD). Methods: In a prospective and randomised study, 25 eyes of 15 patients with mean age of 70 years were analysed....

Read More

Bull’s Eye Maculopathy: Hydroxychloroquine Toxicity or Macular Dystrophy?

Vázquez-Dorrego XM, Ruiz-Bilbao SM, Poposka D, Aranda-Yus A, Hayik B, Broc Iturralde, L. Advantages: Fundus appearance would be documented before starting long-term antipaludic therapy in rheumatologic or dermatologic diseases. Methods: A 34 years old female patient was sent for screening of possible retinal toxicity six months after beginning hydroxichloroquine therapy for systemic lupus erythematosus. To our knowledge, no ophthalmic...

Read More
content top